Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor

医学 内科学 化学免疫疗法 替莫唑胺 伊立替康 进行性疾病 神经母细胞瘤 肿瘤科 粒细胞集落刺激因子 无进展生存期 胃肠病学 外科 化疗 癌症 环磷酰胺 结直肠癌 生物 遗传学 细胞培养
作者
Benjamin Joshua Lerman,Yimei Li,Cecilia A. Carlowicz,Meaghan P. Granger,Thomas Cash,Arhanti Sadanand,Katherine M. Somers,Aeesha Ranavaya,Brian Weiss,Michelle Choe,Jennifer Haunani Foster,Navin R. Pinto,Daniel A. Morgenstern,Margarida Rafael,Keri A. Streby,Rachel N. Zeno,Rajen J. Mody,Sahr Yazdani,Ami Vijay Desai,Margaret E. Macy
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:41 (3): 508-516 被引量:51
标识
DOI:10.1200/jco.22.01273
摘要

PURPOSE: Although chemoimmunotherapy is widely used for treatment of children with relapsed high-risk neuroblastoma (HRNB), little is known about timing, duration, and evolution of response after irinotecan/temozolomide/dinutuximab/granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSF) therapy. PATIENTS AND METHODS: Patients eligible for this retrospective study were age < 30 years at diagnosis of HRNB and received ≥ 1 cycle of I/T/DIN/GM-CSF for relapsed or progressive disease. Patients with primary refractory disease who progressed through induction were excluded. Responses were evaluated using the International Neuroblastoma Response Criteria. RESULTS: -amplified in 50 of 134 (37%). Seventy-one patients (49%) had an objective response to I/T/DIN/GM-CSF (objective response; 29% complete response, 14% partial response [PR], 5% minor response [MR], 21% stable disease [SD], and 30% progressive disease). Of patients with SD or better at first post-I/T/DIN/GM-CSF disease evaluation, 22% had an improved response per International Neuroblastoma Response Criteria on subsequent evaluation (13% of patients with initial SD, 33% with MR, and 41% with PR). Patients received a median of 4.5 (range, 1-31) cycles. The median progression-free survival (PFS) was 13.1 months, and the 1-year PFS and 2-year PFS were 50% and 28%, respectively. The median duration of response was 15.9 months; the median PFS off all anticancer therapy was 10.4 months after discontinuation of I/T/DIN/GM-CSF. CONCLUSION: Approximately half of patients receiving I/T/DIN/GM-CSF for relapsed HRNB had objective responses. Patients with initial SD were unlikely to have an objective response, but > 1 of 3 patients with MR/PR on first evaluation ultimately had complete response. I/T/DIN/GM-CSF was associated with extended PFS in responders both during and after discontinuation of treatment. This study establishes a new comparator for response and survival in patients with relapsed HRNB.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
碰碰车完成签到 ,获得积分10
刚刚
顾矜的应助被灵巧的寄风采纳,获得10
1秒前
orixero的应助被崔正采纳,获得10
1秒前
1秒前
1秒前
葛星完成签到 ,获得积分10
2秒前
猪皮恶人发布了新的文献求助10
2秒前
Christina完成签到,获得积分10
2秒前
2秒前
2秒前
汉堡宝完成签到,获得积分10
3秒前
3秒前
研友_VZG7GZ的应助被Code_king采纳,获得10
3秒前
3秒前
小马甲的应助被Code_king采纳,获得10
3秒前
深情安青的应助被Code_king采纳,获得10
3秒前
可爱的函函的应助被Code_king采纳,获得10
3秒前
molihuakai的应助被Code_king采纳,获得10
3秒前
3秒前
星辰大海的应助被Code_king采纳,获得10
3秒前
专注凌文发布了新的文献求助10
3秒前
爆米花的应助被Code_king采纳,获得10
3秒前
FashionBoy的应助被Code_king采纳,获得10
4秒前
斯文败类的应助被Code_king采纳,获得10
4秒前
4秒前
Jun的应助被leey采纳,获得10
4秒前
4秒前
小二郎的应助被小天采纳,获得10
4秒前
4秒前
4秒前
4秒前
5秒前
why完成签到 ,获得积分10
5秒前
LJQ发布了新的文献求助10
5秒前
hhuan完成签到,获得积分10
6秒前
bkagyin的应助被酷炫的大碗采纳,获得10
6秒前
6秒前
liumeiyu完成签到,获得积分10
6秒前
细心天奇发布了新的文献求助30
6秒前
张佳琪完成签到,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8176287
求助须知:如何正确求助?哪些是违规求助? 9567719
关于积分的说明 21794359
捐赠科研通 7771008
什么是DOI,文献DOI怎么找? 3431998
关于科研通互助平台的介绍 2556315
邀请新用户注册赠送积分活动 2477650